Get the Stockscreener App
11.76
4.31%
-0.53
After Hours:
11.76
Korro Bio Inc stock is traded at $11.76, with a volume of 252.23K.
It is down -4.31% in the last 24 hours and up +31.54% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$12.29
Open:
$12.3
24h Volume:
252.23K
Relative Volume:
0.53
Market Cap:
$110.75M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-1.1604
EPS:
-10.1344
Net Cash Flow:
$-82.84M
1W Performance:
+1.91%
1M Performance:
+31.54%
6M Performance:
-26.45%
1Y Performance:
-60.47%
1-Day Range:
$10.81
$12.46
1-Week Range:
$10.81
$12.81
52-Week Range:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
11.76 | 115.74M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of "Hold" by Brokerages - MarketBeat
H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO) - MSN
Is FHN.PRB stock a good pick for beginnersJuly 2025 Analyst Calls & Precise Entry and Exit Recommendations - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Korro Bio (KRRO) and AstraZeneca (AZN) - The Globe and Mail
HC Wainwright Brokers Lower Earnings Estimates for Korro Bio - Defense World
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? - Nasdaq
Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Pfizer (PFE) and Alpha Teknova (TKNO) - The Globe and Mail
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential By Investing.com - Investing.com Nigeria
Korro Bio's KRRO-121 Receives Strong Analyst Upgrades - intellectia.ai
Korro Bio Shares Rise After Piper Sandler, HC Wainwright Upgrades - marketscreener.com
Korro Bio stock rating upgraded by H.C. Wainwright to Buy on new drug potential - Investing.com Canada
Piper Sandler Upgrades Korro Bio to Overweight From Neutral, Adjusts Price Target to $30 From $11 - marketscreener.com
HC Wainwright Upgrades Korro Bio to Buy From Neutral, Price Target is $20 - marketscreener.com
This Fortinet Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
HC Wainwright & Co. Upgrades Korro Bio (KRRO) - Nasdaq
KRRO Shares Jump 13% On Analyst UpgradesWhat's Driving The Optimism? - Mena FN
Piper Sandler upgrades Korro Bio stock rating to Overweight on UCD treatment - Investing.com Nigeria
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential - Investing.com India
Oppenheimer Upgrades Korro Bio (KRRO) - Nasdaq
Korro Bio Shares Rise After Oppenheimer Upgrade - marketscreener.com
Raymond James reiterates Market Perform rating on Korro Bio stock By Investing.com - Investing.com India
Cantor Fitzgerald Upgrades Korro Bio to Overweight From Neutral - marketscreener.com
William Blair reiterates Market Perform rating on Korro Bio stock By Investing.com - Investing.com Canada
Raymond James reiterates Market Perform rating on Korro Bio stock - Investing.com
William Blair reiterates Market Perform rating on Korro Bio stock - Investing.com
Cantor Fitzgerald upgrades Korro Bio stock to Overweight on UCD program By Investing.com - Investing.com South Africa
Cantor Fitzgerald upgrades Korro Bio stock to Overweight on UCD program - Investing.com
Korro Bio stock holds steady as Jones Trading reiterates Hold rating - Investing.com
Clear Street raises Korro Bio stock price target to $10 on new lead program - Investing.com Nigeria
Clear Street raises Korro Bio stock price target to $10 on new lead program By Investing.com - Investing.com South Africa
Korro Bio Showcases KRRO-121 RNA Editing Program Progress - TipRanks
Korro Bio, Inc. Unveils KRRO-121 as a Potential First-in-Class Treatment - TradingView
Investor Mood: Does Red Rock Resorts Inc have strong fundamentalsJuly 2025 Patterns & Reliable Intraday Trade Alerts - baoquankhu1.vn
Moving Averages: Will Korro Bio Inc benefit from green energy policiesMarket Sentiment Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Growth Recap: Should I buy Korro Bio Inc stock now2025 Volume Leaders & Safe Capital Growth Stock Tips - baoquankhu1.vn
Korro to Host Virtual Analyst Day on January 27, 2026 - The Manila Times
Parent and liver doctor join Korro Bio to explain ammonia-driven diseases - Stock Titan
FOMO Trade: Should you avoid Korro Bio Inc stock right nowJuly 2025 Price Swings & Verified Momentum Stock Ideas - baoquankhu1.vn
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):